FDA’s Priority Reviews May Have Helped Reduce New Drug Shortages
But agency's policy changes have failed to ameliorate ongoing shortages, GAO finds.
You may also be interested in...
GAO's 'high risk' report lowers FDA grade for its drug shortage action plans, saying efforts have not been sustained.
In theory, reviewing generic applications faster should speed competition; in practice, FDA's new policy likely won't make too much difference.
Manufacturers shouldn’t be afraid to work with FDA on preventing drug shortages for fear of public shaming, agency says.